Supernus Pharmaceuticals SUPN
NASDAQ SUPN
$41.25 +0.02 (+0.05%)
As of: Oct 21, 2026 · 11:41 AM EDT

Supernus Pharmaceuticals (SUPN) Current Deferred Revenue (2011 - 2017)

Updated

Supernus Pharmaceuticals (SUPN) reported Current Deferred Revenue of $287,000 for Q4 2017.

Analysis

Supernus Pharmaceuticals (SUPN) Current Deferred Revenue (2011 - 2017) Analysis & Trends

Dating back to Q4 2011, Supernus Pharmaceuticals' Current Deferred Revenue record includes 8 quarters.

  • Current Deferred Revenue has a five-year compound annual growth rate of -10.8% (FY2012 to FY2017).
  • The Q4 2017 figure ranks as the highest quarterly Current Deferred Revenue since Q4 2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.81 Bn 19.71 Bn
2 Johnson & Johnson 613.62 Bn 532.15 Bn 17.26 Bn
3 AbbVie 501.46 Bn 474.57 Bn 12.70 Bn
4 Merck 366.84 Bn 321.22 Bn 12.21 Bn
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn
7 Amgen 235.39 Bn 190.79 Bn 7.24 Bn
8 Gilead Sciences 190.66 Bn 164.86 Bn 6.22 Bn
9 Pfizer 169.57 Bn 116.22 Bn 10.94 Bn
10 Supernus Pharmaceuticals 2.40 Bn 1.06 Bn 185.39 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 287,000.00
Sep 30, 2015 100,000.00
Jun 30, 2015 100,000.00
Dec 31, 2012 508,000.00
Sep 30, 2012 576,000.00
Jun 30, 2012 365,000.00
Mar 31, 2012 232,000.00
Dec 31, 2011 232,000.00
API Access

Supernus Pharmaceuticals Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=SUPN&period=max&api_key=YOUR_API_KEY